Proximity Ligation Assay to Detect DUX4 Protein in FSHD1 Muscle: a Pilot Study

Overview

Journal BMC Res Notes

Publisher Biomed Central

Specialties Biology
General Medicine

Date 2022 May 10

PMID 35538497

Authors

Mary Lou Beermann

Sachiko Homma

Jeffrey Boone Miller

Affiliations

Soon will be listed here.

Abstract

Objective: Aberrant expression in skeletal muscle of DUX4, a double homeobox transcription factor, underlies pathogenesis in facioscapulohumeral muscular dystrophy (FSHD). Although previous studies of FSHD muscle biopsies detected mRNAs encoding DUX4 and its target genes, no studies had reported detection of DUX4 protein. Our objective was to develop a proximity ligation assay (PLA) for DUX4 and to determine if this assay could detect DUX4 protein in FSHD muscle sections.

Results: We developed a PLA protocol using two DUX4 antibodies previously reported by Stephen Tapscott's group: P2G4, a mouse mAb specific for an epitope in the N-terminal region, and E5-5, a rabbit mAb specific for an epitope in the C-terminal region, in combination with commercial PLA secondary reagents. We validated the DUX4 PLA using cultured human myogenic cells in which DUX4 was ectopically expressed in a small fraction of nuclei. Using this two primary mAb PLA on an FSHD1 biceps biopsy, we observed nuclei with apparent DUX4 PLA signals associated with a small subset of myofibers (~ 0.05-0.1%). Though a limited pilot study, these results suggest that the two primary mAb PLA protocol could be useful for detecting DUX4 protein in FSHD muscle biopsies.

Citing Articles

Temporal variation in p38-mediated regulation of DUX4 in facioscapulohumeral muscular dystrophy.

Vangipurapu R, Oliva J, Fox A, Sverdrup F Sci Rep. 2024; 14(1):26437.

PMID: 39488616 PMC: 11531483. DOI: 10.1038/s41598-024-77911-8.

snRNA-seq analysis in multinucleated myogenic FSHD cells identifies heterogeneous FSHD transcriptome signatures associated with embryonic-like program activation and oxidative stress-induced apoptosis.

Zheng D, Wondergem A, Kloet S, Willemsen I, Balog J, Tapscott S Hum Mol Genet. 2023; 33(3):284-298.

PMID: 37934801 PMC: 10800016. DOI: 10.1093/hmg/ddad186.

An in silico FSHD muscle fiber for modeling DUX4 dynamics and predicting the impact of therapy.

Cowley M, Pruller J, Ganassi M, Zammit P, Banerji C Elife. 2023; 12.

PMID: 37184373 PMC: 10287159. DOI: 10.7554/eLife.88345.

The double homeodomain protein DUX4c is associated with regenerating muscle fibers and RNA-binding proteins.

Claus C, Slavin M, Ansseau E, Lancelot C, Bah K, Lassche S Skelet Muscle. 2023; 13(1):5.

PMID: 36882853 PMC: 9990282. DOI: 10.1186/s13395-022-00310-y.

Facioscapulohumeral muscular dystrophy: the road to targeted therapies.

Tihaya M, Mul K, Balog J, de Greef J, Tapscott S, Tawil R Nat Rev Neurol. 2023; 19(2):91-108.

PMID: 36627512 PMC: 11578282. DOI: 10.1038/s41582-022-00762-2.

References

Tassin A, Laoudj-Chenivesse D, Vanderplanck C, Barro M, Charron S, Ansseau E . DUX4 expression in FSHD muscle cells: how could such a rare protein cause a myopathy?. J Cell Mol Med. 2012; 17(1):76-89. PMC: 3823138. DOI: 10.1111/j.1582-4934.2012.01647.x. View

Mitsuhashi H, Ishimaru S, Homma S, Yu B, Honma Y, Beermann M . Functional domains of the FSHD-associated DUX4 protein. Biol Open. 2018; 7(4). PMC: 5936065. DOI: 10.1242/bio.033977. View

Nunes A, Ramirez M, Jones T, Jones P . Identification of candidate miRNA biomarkers for facioscapulohumeral muscular dystrophy using DUX4-based mouse models. Dis Model Mech. 2021; 14(8). PMC: 8405850. DOI: 10.1242/dmm.049016. View

Wang L, Tawil R . Facioscapulohumeral Dystrophy. Curr Neurol Neurosci Rep. 2016; 16(7):66. DOI: 10.1007/s11910-016-0667-0. View

Jones T, Chen J, Rahimov F, Homma S, Arashiro P, Beermann M . Facioscapulohumeral muscular dystrophy family studies of DUX4 expression: evidence for disease modifiers and a quantitative model of pathogenesis. Hum Mol Genet. 2012; 21(20):4419-30. PMC: 3459465. DOI: 10.1093/hmg/dds284. View

Lemmers R, van der Vliet P, Klooster R, Sacconi S, Camano P, Dauwerse J . A unifying genetic model for facioscapulohumeral muscular dystrophy. Science. 2010; 329(5999):1650-3. PMC: 4677822. DOI: 10.1126/science.1189044. View

Jones T, Chew G, Barraza-Flores P, Schreier S, Ramirez M, Wuebbles R . Transgenic mice expressing tunable levels of DUX4 develop characteristic facioscapulohumeral muscular dystrophy-like pathophysiology ranging in severity. Skelet Muscle. 2020; 10(1):8. PMC: 7149937. DOI: 10.1186/s13395-020-00227-4. View

Himeda C, Debarnot C, Homma S, Beermann M, Miller J, Jones P . Myogenic enhancers regulate expression of the facioscapulohumeral muscular dystrophy-associated DUX4 gene. Mol Cell Biol. 2014; 34(11):1942-55. PMC: 4019064. DOI: 10.1128/MCB.00149-14. View

Soderberg O, Leuchowius K, Gullberg M, Jarvius M, Weibrecht I, Larsson L . Characterizing proteins and their interactions in cells and tissues using the in situ proximity ligation assay. Methods. 2008; 45(3):227-32. DOI: 10.1016/j.ymeth.2008.06.014. View

10.

Geng L, Tyler A, Tapscott S . Immunodetection of human double homeobox 4. Hybridoma (Larchmt). 2011; 30(2):125-30. PMC: 3132944. DOI: 10.1089/hyb.2010.0094. View

11.

Lemmers R, van der Vliet P, Blatnik A, Balog J, Zidar J, Henderson D . Chromosome 10q-linked FSHD identifies as principal disease gene. J Med Genet. 2021; 59(2):180-188. PMC: 8273184. DOI: 10.1136/jmedgenet-2020-107041. View

12.

Krom Y, Thijssen P, Young J, den Hamer B, Balog J, Yao Z . Intrinsic epigenetic regulation of the D4Z4 macrosatellite repeat in a transgenic mouse model for FSHD. PLoS Genet. 2013; 9(4):e1003415. PMC: 3616921. DOI: 10.1371/journal.pgen.1003415. View

13.

Banerji C, Zammit P . Pathomechanisms and biomarkers in facioscapulohumeral muscular dystrophy: roles of DUX4 and PAX7. EMBO Mol Med. 2021; 13(8):e13695. PMC: 8350899. DOI: 10.15252/emmm.202013695. View

14.

Homma S, Beermann M, Boyce F, Miller J . Expression of FSHD-related DUX4-FL alters proteostasis and induces TDP-43 aggregation. Ann Clin Transl Neurol. 2015; 2(2):151-66. PMC: 4338956. DOI: 10.1002/acn3.158. View

15.

Mitsuhashi H, Homma S, Beermann M, Ishimaru S, Takeda H, Yu B . Efficient system for upstream mRNA trans-splicing to generate covalent, head-to-tail, protein multimers. Sci Rep. 2019; 9(1):2274. PMC: 6381186. DOI: 10.1038/s41598-018-36684-7. View

16.

Rickard A, Petek L, Miller D . Endogenous DUX4 expression in FSHD myotubes is sufficient to cause cell death and disrupts RNA splicing and cell migration pathways. Hum Mol Genet. 2015; 24(20):5901-14. PMC: 4581613. DOI: 10.1093/hmg/ddv315. View

17.

Masteika I, Sathya A, Homma S, Miller B, Boyce F, Miller J . Downstream events initiated by expression of FSHD-associated DUX4: Studies of nucleocytoplasmic transport, γH2AX accumulation, and Bax/Bak-dependence. Biol Open. 2022; 11(2). PMC: 8890089. DOI: 10.1242/bio.059145. View

18.

Raykova D, Koos B, Asplund A, Gelleri M, Ivarsson Y, Danielson U . Let There Be Light!. Proteomes. 2017; 4(4). PMC: 5260969. DOI: 10.3390/proteomes4040036. View

19.

Campbell A, Belleville A, Resnick R, Shadle S, Tapscott S . Facioscapulohumeral dystrophy: activating an early embryonic transcriptional program in human skeletal muscle. Hum Mol Genet. 2018; 27(R2):R153-R162. PMC: 6061842. DOI: 10.1093/hmg/ddy162. View

20.

Greenwood C, Ruff D, Kirvell S, Johnson G, Dhillon H, Bustin S . Proximity assays for sensitive quantification of proteins. Biomol Detect Quantif. 2016; 4:10-6. PMC: 4822221. DOI: 10.1016/j.bdq.2015.04.002. View